Pricing updated 2019-07-17. Prices are subject to change without notice.
C18 Ceramide is an endogenous bioactive sphingolipid. It is the primary short-chain ceramide found in brain tissue whose synthesis is regulated by longevity-assurance homologue 1 (Lass1) in mice.1 Increased expression of C18 ceramide reduces cell growth in UM-SCC-22A squamous cell carcinoma cells.2 It is selectively downregulated in 32 human head and neck squamous cell carcinoma tumor tissues as compared to non-squamous tumor tissues. C18 Ceramide concentration is significantly higher in muscle tissue of type 2 diabetic patients compared with non-diabetic patients and is positively correlated to body mass index and inversely related to insulin sensitivity.3
Warning - this product is not for human or veterinary use.
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.
1. Mizutani, Y., Kihara, A., and Igarashi, Y. Mammalian Lass6 and its related family members regulate synthesis of specific ceramides Biochem J. 390(Pt. 1), 263-271 (2005).
Koybasi, S., Senkal, C.E., Sundararaj, K., et al. Defects in cell growth regulation by C18:0-
3. Bergman, B.C., Brozinick, J.T., Strauss, A., et al. Muscle sphingolipids during rest and exercise: A C18:0 signature for insulin resistance in humans Diabetologia 59(3), 785-791 (2016).